| CARVIEW |
Select Language
HTTP/2 301
date: Sun, 25 Jan 2026 21:27:19 GMT
content-type: text/html
content-length: 166
location: https://www.apollo.vc/
server: cloudflare
cf-ray: 9c3ada97bfe77fa8-BLR
cf-cache-status: BYPASS
cache-control: private
strict-transport-security: max-age=31536000
vary: Accept-Encoding
set-cookie: _cfuvid=r_hg8Gnhxe8CrRly11qfSdKrflK2MwhJtZ6OhlKITN8-1769376439685-0.0.1.1-604800000; path=/; domain=.apollo.vc; HttpOnly; Secure; SameSite=None
alt-svc: h3=":443"; ma=86400
HTTP/2 200
date: Sun, 25 Jan 2026 21:27:20 GMT
content-type: text/html
server: cloudflare
cf-ray: 9c3ada9c4ea2a555-BLR
cf-cache-status: HIT
content-encoding: gzip
last-modified: Thu, 22 Jan 2026 04:59:55 GMT
strict-transport-security: max-age=31536000
surrogate-control: max-age=432000
surrogate-key: www.apollo.vc 643fb2e9791f1921704a2720 pageId:643fb2e9791f195d324a2721 6446f0eb5684ddc9e393dad2 64459a11ae731edd69522eeb
x-lambda-id: 40196429-0337-4612-b7ee-2533830bdc16
vary: Accept-Encoding
alt-svc: h3=":443"; ma=86400
Apollo Health Ventures
Join us on LinkedIn for the latest news.
Building Next Generation Companies To Enhance Healthy Lifespan
Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself.
Learn more
Biotechnology is the solution for a healthier lifespan and reduced healthcare spending.
By investing and thus enabling transformative healthcare companies in their scientific breakthroughs, we will impact human health within the next 10 years.
News & Press
News from our portfolio companies, recent advances in biotech, health tech and investments.
29.5.2025
Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
14.5.2025
Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
8.5.2025
HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
24.2.2025
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
4.2.2025
Auron Therapeutics secures FDA clearance & $27M Series B to advance precision oncology
10.10.2024
Booster Therapeutics launches with $15 M seed financing led by Apollo Health Ventures and Novo Holdings
Investment Strategy
We leverage potential by combining traditional funding with venture building, accomplishing a bigger and more diverse value creation in Europe and the US.
ACTIVE VENTURE CREATION
In our Venture Lab, we partner with scientific experts and turn untapped technologies into transformational companies. This way we acquire founder shares at nominal value– offering unique upsides to our investors.
Scientific & operational expertise
Building top teams
Access to capital & strong syndicates
Risk minimization by conducting killer experiments
Investing in best-in-class companies
Alongside of our venture lab approach, we generate additional value by identifying best-in-class companies at an early stage. Based on breakthrough science and led by amazing founders, we help those companies accelerate.
ACCESS
Access through extensive network and trust due to our deep knowledge
Successful track record since 2017
Accelerate
Leading players in follow on investment rounds
Support by talent and leadership recruitment, guidance on R&D as well as clinical trial and indication selection strategies.
Join us on LinkedIn for the latest news.